7.35
price up icon0.96%   0.07
pre-market  プレマーケット:  7.45   0.10   +1.36%
loading
前日終値:
$7.28
開ける:
$7.24
24時間の取引高:
549.46K
Relative Volume:
1.28
時価総額:
$208.91M
収益:
$67.22M
当期純損益:
$-65.78M
株価収益率:
-3.0796
EPS:
-2.3867
ネットキャッシュフロー:
$-79.02M
1週間 パフォーマンス:
+7.77%
1か月 パフォーマンス:
+0.68%
6か月 パフォーマンス:
+11.20%
1年 パフォーマンス:
-46.66%
1日の値動き範囲:
Value
$7.13
$7.66
1週間の範囲:
Value
$6.69
$8.28
52週間の値動き範囲:
Value
$5.85
$24.17

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name
名前
Arcturus Therapeutics Holdings Inc
Name
セクター
Healthcare (1100)
Name
電話
(858) 900-2660
Name
住所
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
111
Name
Twitter
@ArcturusRx
Name
次回の収益日
2026-08-10
Name
最新のSEC提出書
Name
ARCT's Discussions on Twitter

Compare ARCT vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ARCT icon
ARCT
Arcturus Therapeutics Holdings Inc
7.35 191.00M 67.22M -65.78M -79.02M -2.3867
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
529.59 126.07B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
649.81 65.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
916.80 57.70B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
313.04 40.19B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
189.99 39.82B 742.00K -1.37B -1.07B -7.0731

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-18 開始されました B. Riley Securities Buy
2026-01-23 開始されました Roth Capital Buy
2025-10-24 ダウングレード H.C. Wainwright Buy → Neutral
2025-10-23 ダウングレード Citigroup Buy → Neutral
2025-10-22 ダウングレード Guggenheim Buy → Neutral
2025-09-04 再開されました H.C. Wainwright Buy
2025-05-28 開始されました Scotiabank Sector Outperform
2025-01-28 開始されました BTIG Research Buy
2024-08-12 開始されました Leerink Partners Outperform
2023-12-13 開始されました Canaccord Genuity Buy
2023-07-24 開始されました William Blair Outperform
2023-05-11 アップグレード H.C. Wainwright Neutral → Buy
2022-11-14 再開されました Wells Fargo Overweight
2022-11-10 ダウングレード Robert W. Baird Neutral → Underperform
2022-11-03 アップグレード Citigroup Neutral → Buy
2022-11-02 アップグレード Barclays Underweight → Equal Weight
2022-08-10 ダウングレード Raymond James Mkt Perform → Underperform
2022-07-19 再開されました Cantor Fitzgerald Overweight
2022-05-11 アップグレード Robert W. Baird Underperform → Neutral
2022-04-21 ダウングレード Citigroup Buy → Neutral
2022-01-31 アップグレード Raymond James Underperform → Mkt Perform
2021-08-12 ダウングレード Raymond James Mkt Perform → Underperform
2021-08-11 ダウングレード Goldman Neutral → Sell
2021-08-10 ダウングレード Robert W. Baird Neutral → Underperform
2021-07-02 開始されました Cantor Fitzgerald Overweight
2021-06-25 再開されました Goldman Neutral
2021-06-21 ダウングレード Barclays Equal Weight → Underweight
2021-06-04 再開されました Robert W. Baird Neutral
2021-02-17 ダウングレード B. Riley Securities Neutral → Sell
2021-01-19 ダウングレード B. Riley Securities Buy → Neutral
2021-01-15 ダウングレード B. Riley Securities Buy → Neutral
2021-01-07 開始されました Wells Fargo Overweight
2020-12-29 ダウングレード Barclays Overweight → Equal Weight
2020-12-29 ダウングレード H.C. Wainwright Buy → Neutral
2020-12-29 ダウングレード Raymond James Outperform → Mkt Perform
2020-12-29 ダウングレード Robert W. Baird Outperform → Neutral
2020-12-23 ダウングレード ROTH Capital Buy → Sell
2020-12-08 繰り返されました B. Riley Securities Buy
2020-12-07 繰り返されました B. Riley Securities Buy
2020-10-26 開始されました Barclays Overweight
2020-10-06 開始されました Citigroup Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-30 再開されました ROTH Capital Buy
2020-07-16 開始されました Raymond James Outperform
2020-07-13 開始されました B. Riley FBR Buy
2020-06-09 ダウングレード WBB Securities Buy → Hold
2020-02-11 開始されました Robert W. Baird Outperform
2020-02-07 開始されました Guggenheim Buy
2020-02-06 開始されました Guggenheim Buy
2019-04-05 開始されました H.C. Wainwright Buy
2018-09-20 アップグレード WBB Securities Buy → Strong Buy
2018-01-22 開始されました Chardan Capital Markets Buy
すべてを表示

Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース

pulisher
Jul 02, 2026

Arcturus partners with Thermo Fisher for cystic fibrosis drug - Investing.com

Jul 02, 2026
pulisher
Jul 02, 2026

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Business Wire

Jul 02, 2026
pulisher
Jul 01, 2026

Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView

Jul 01, 2026
pulisher
Jun 29, 2026

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBITDA forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBIT forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView

Jun 28, 2026
pulisher
Jun 26, 2026

Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

ARCT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 25, 2026
pulisher
Jun 21, 2026

Discipline and Rules-Based Execution in ARCT Response - Stock Traders Daily

Jun 21, 2026
pulisher
Jun 19, 2026

ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 19, 2026
pulisher
Jun 18, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

ARCT Q1 2026 Earnings: Narrower-than-expected loss highlights clinical momentumMid-Term Outlook - newsline.com

Jun 17, 2026
pulisher
Jun 16, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Arcturus Therapeutics Holdings Inc - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Institutional Confidence - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 16, 2026
pulisher
Jun 15, 2026

Arcturus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HOLMES EDWARD W - Moomoo

Jun 15, 2026
pulisher
Jun 15, 2026

Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30 - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 12, 2026

Arcturus Therapeutics highlights mRNA pipeline, CF data and vaccine expansion at Jefferies - MSN

Jun 12, 2026
pulisher
Jun 10, 2026

ARCT Q1 2026 Earnings: Narrower-than-Expected Loss Despite No RevenueProfit Margin Analysis - Město Břeclav

Jun 10, 2026
pulisher
Jun 09, 2026

Behavioral Patterns of ARCT and Institutional Flows - Stock Traders Daily

Jun 09, 2026
pulisher
Jun 08, 2026

mRNA Vaccines and Therapeutics Market Size, Share, Growth, 2034 - Straits Research

Jun 08, 2026
pulisher
Jun 06, 2026

Arcturus Therapeutics Holdings Inc. 2026 Annual Shareholder Meeting Results and Election of Directors - Minichart

Jun 06, 2026
pulisher
Jun 05, 2026

Arcturus Shareholders Back Board, Pay, and Auditor - TipRanks

Jun 05, 2026
pulisher
Jun 05, 2026

Arcturus Therapeutics (ARCT) holders elect board, approve pay and auditor - Stock Titan

Jun 05, 2026
pulisher
Jun 05, 2026

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies - inkl

Jun 05, 2026
pulisher
Jun 04, 2026

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Jun 04, 2026
pulisher
Jun 02, 2026

Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next - Bez Kabli

Jun 02, 2026
pulisher
May 31, 2026

Arcturus Therapeutics Holds Steady at $7.92 as Market Awaits CatalystsMomentum ETF - newsline.com

May 31, 2026
pulisher
May 29, 2026

(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

May 29, 2026
pulisher
May 29, 2026

Is Arcturus Therapeutics Poised for a Massive Upside in 2026 - Kavout

May 29, 2026
pulisher
May 29, 2026

Arcturus Therapeutics (ARCT) Holds Steady at $7.92 – Waiting for a CatalystTriple EMA - newsline.com

May 29, 2026
pulisher
May 28, 2026

Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026 - Traders Union

May 28, 2026
pulisher
May 28, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

May 28, 2026
pulisher
May 27, 2026

Arcturus Therapeutics (ARCT) Surges 6.2% as Buyers Defend Key SupportFibonacci Extension - thelegaladvocate.com

May 27, 2026
pulisher
May 27, 2026

Arcturus Therapeutics urges new solutions as 10 percent of cystic fibrosis patients still lack effective treatment - Traders Union

May 27, 2026
pulisher
May 26, 2026

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace

May 26, 2026

Arcturus Therapeutics Holdings Inc (ARCT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$111.54
price down icon 0.05%
$56.92
price down icon 1.47%
$35.39
price up icon 0.74%
ONC ONC
$309.46
price up icon 3.97%
$81.80
price up icon 2.56%
$189.99
price up icon 0.40%
大文字化:     |  ボリューム (24 時間):